12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-23), Evolus's 12-1 Month Momentum % is 50.93%.
The industry rank for Evolus's 12-1 Month Momentum % or its related term are showing as below:
EOLS's 12-1 Month Momentum % is ranked better than 84.17% of 1112
companies
in the Drug Manufacturers industry
Industry Median: -5.885
vs EOLS: 50.93
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus 12-1 Month Momentum % Distribution
For the Drug Manufacturers industry and Healthcare sector, Evolus's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Evolus's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Evolus 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Evolus's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare, or commercial insurance. It generates product revenue from the sale of Jeuveau in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EOLS has been successfully added to your